{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.7","upperLimit":"28.6","value":"22.7"},{"groupId":"OG001","lowerLimit":"10.8","upperLimit":"19.8","value":"14.7"},{"groupId":"OG002","lowerLimit":"9.1","upperLimit":"16.0","value":"13.3"},{"groupId":"OG003","lowerLimit":"7.4","upperLimit":"20.1","value":"14.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"107"},{"groupId":"OG003","value":"23"}],"units":"Participants"}],"description":"Overall survival (OS) is defined as the number of days from the date of first dose of study drug to the date of death (due to any cause). Patients without a known date of death will be censored on the date the patient was last known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with a deleterious BRCA mutation detected in their tumor.","id":"OG000","title":"Part 2: tBRCA"},{"description":"Patients without a BRCA mutation in their tumor, but have high LOH.","id":"OG001","title":"Part 2: Non-tBRCA LOH+"},{"description":"Patients without a BRCA mutation in their tumor, but have low LOH.","id":"OG002","title":"Part 2: Non-tBRCA LOH-"},{"description":"Patients without a BRCA mutation in their tumor, and have unknown LOH due to missing results and/or failed test result(s).","id":"OG003","title":"Part 2: Non-tBRCA LOH Unknown"}],"paramType":"MEDIAN","populationDescription":"Safety population by HRD subgroups: Consist of all Part 2 patients who received at least one dose of rucaparib.","reportingStatus":"POSTED","timeFrame":"All patients in Part 2 were followed for survival, subsequent therapy, and secondary malignancy every 12 weeks until death, loss to follow-up, withdrawal of consent from study or study closure, whichever happened first, up to 7 years.","title":"Overall Survival (Part 2 of Study)","type":"SECONDARY","unitOfMeasure":"Months"}